|

RP2D of FC084CSA+Tislelizumab combination (dose expansion) Clinical Trials

1 actively recruiting trial

Also known as: RP2D of FC084CSA+BGB-A317 combination (dose expansion)

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.